DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Saxenda"


2 mentions found


☆ Big Pharma will muscle in on obesity gold rush
  + stars: | 2022-11-28 | by ( Aimee Donnellan | ) www.reuters.com   time to read: +4 min
LONDON, Nov 28 (Reuters Breakingviews) - Obesity drugs are a modern day gold rush for drugmakers. By then, the obesity market could total $50 billion, according to Morgan Stanley. But a plausible 50% price cut would lower annual sales to $25 billion. Reuters GraphicsFollow @aimeedonnellan on TwitterCONTEXT NEWSSales of Novo Nordisk’s obesity drugs Wegovy and Saxenda reached nearly $1.2 billion in 2021, up 50% versus the previous year. Morgan Stanley analysts expect the obesity market to grow to $50 billion in annual sales by 2030.
☆ New obesity drugs win support of doctors and insurers, which could lift these pharma names even higher
  + stars: | 2022-11-03 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +5 min
They are also increasingly being prescribed by doctors and covered by insurers – a win for patients and for investors. According to Novo Nordisk , the maker of weight-loss drug Wegovy, about 80% of anti-obesity medications are being covered by health insurers, Meacham said. Novo's semaglutide is branded Wegovy as a weight-loss treatment and Ozempic for the treatment of type 2 diabetes. When combined with lifestyle modifications, patients taking Wegovy can sustain a 15% weight loss , according to late-stage clinical trial data. Eli Lilly has a competing drug, Mounjaro, that uses both GLP-1 and a second incretin, glucose-dependent insulinotropic polypeptide, or GIP.
<< prev 2 next >>
Total: 2